Adimmune Corporation, a leading biopharmaceutical company based in Taiwan (TW), has been at the forefront of vaccine development since its establishment in 1965. With a strong focus on the research, production, and distribution of vaccines, Adimmune has made significant strides in enhancing public health both locally and internationally. The company is renowned for its innovative vaccine solutions, including those for influenza and other infectious diseases, which are distinguished by their high efficacy and safety profiles. Adimmune's commitment to quality and research excellence has positioned it as a key player in the global vaccine market. Over the years, Adimmune has achieved numerous milestones, solidifying its reputation as a trusted provider of vaccines. Its strategic operations extend beyond Taiwan, reaching various regions, thereby contributing to global health initiatives and responding to emerging health challenges.
How does Adimmune Corporation's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Adimmune Corporation's score of 21 is lower than 75% of the industry. This can give you a sense of how well the company is doing compared to its peers.
In 2023, Adimmune Corporation, headquartered in Taiwan (TW), reported total carbon emissions of approximately 16,779,000 kg CO2e. This figure includes 4,556,000 kg CO2e from Scope 1 emissions and 12,223,000 kg CO2e from Scope 2 emissions. The company's emissions data reflects a slight decrease from 2022, when total emissions were about 16,395,000 kg CO2e, with Scope 1 and Scope 2 emissions of 4,572,000 kg CO2e and 11,823,000 kg CO2e, respectively. Adimmune has not disclosed any Scope 3 emissions data, nor have they set specific reduction targets or initiatives as part of their climate commitments. The absence of documented reduction targets suggests that the company may be in the early stages of formalising its climate strategy. Overall, Adimmune Corporation's emissions profile indicates a commitment to monitoring and reporting its carbon footprint, although further steps may be necessary to establish clear reduction goals and initiatives in line with industry standards.
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | |
|---|---|---|---|
| Scope 1 | 3,215,000 | 0,000,000 | 0,000,000 | 
| Scope 2 | 9,265,000 | 00,000,000 | 00,000,000 | 
| Scope 3 | - | - | - | 
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Adimmune Corporation has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
